• ArriVent Biopharma will present initial Phase 1 safety and efficacy data for ARR-217 in gastrointestinal cancers at ESMO on October 25, 2026.
• The first-in-human study evaluates the CDH17-targeted antibody-drug conjugate, also known as MRG007, in patients with locally advanced or metastatic solid tumors.
• A virtual webinar on October 26, 2026, at 8 a.m. ET will discuss the data and development program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231600PRIMZONEFULLFEED9852184) on October 23, 2026, and is solely responsible for the information contained therein.